Lilly signs oncology research deal with Stipple Bio worth up to $5.9 billion
Lilly signs oncology research deal with Stipple Bio worth up to $5.9 billion Nov 16 (Reuters) - Eli Lilly LLY.N has signed an oncology research collaboration and licensing agreement worth up to $5.9 billion with private biotechnology firm Stipple Bio, the companies said on Monday.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Sahal Muhammed)
Recent news on Eli Lilly and
See all newsBiogen's anti-tau Alzheimer's drug benefits increase at 2 years
Eli Lilly’s $1.4 trln valuation is heavy with hope
Lilly signs cancer research deal with Stipple Bio worth up to $5.9 billion (updated)
Brief: Stipple Bio Enters Multi-Target Oncology Collaboration With Eli Lilly
Deals of the day-Mergers and acquisitions